Sanofi (NASDAQ:SNY) Given New €115.00 Price Target at JPMorgan Chase & Co.

Sanofi (NASDAQ:SNYGet Rating) had its price target raised by JPMorgan Chase & Co. from €105.00 ($108.25) to €115.00 ($118.56) in a research note released on Monday, The Fly reports.

Several other equities research analysts have also commented on SNY. UBS Group boosted their price target on shares of Sanofi from €118.00 ($121.65) to €119.00 ($122.68) and gave the stock a buy rating in a report on Tuesday, June 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Sanofi from €85.00 ($87.63) to €90.00 ($92.78) and gave the stock a sell rating in a research note on Friday. SVB Leerink started coverage on shares of Sanofi in a research note on Monday, May 23rd. They set an outperform rating on the stock. Barclays lifted their target price on shares of Sanofi from €90.00 ($92.78) to €105.00 ($108.25) in a research note on Thursday, April 14th. Finally, Guggenheim boosted their price target on shares of Sanofi from €121.00 ($124.74) to €127.00 ($130.93) in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $111.14.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.90 on Monday. The firm has a market cap of $123.76 billion, a PE ratio of 16.25, a PEG ratio of 1.23 and a beta of 0.48. The firm has a fifty day moving average of $51.32 and a 200 day moving average of $52.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29. Sanofi has a one year low of $46.92 and a one year high of $58.10.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently bought and sold shares of SNY. Boston Partners raised its holdings in Sanofi by 62.3% in the 1st quarter. Boston Partners now owns 11,272,368 shares of the company’s stock valued at $580,302,000 after buying an additional 4,328,799 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the period. Bank of America Corp DE increased its stake in Sanofi by 14.4% during the first quarter. Bank of America Corp DE now owns 12,051,921 shares of the company’s stock worth $618,746,000 after purchasing an additional 1,512,434 shares during the period. Goldman Sachs Group Inc. increased its stake in Sanofi by 29.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,227,680 shares of the company’s stock worth $111,607,000 after purchasing an additional 506,752 shares during the period. Finally, Aaron Wealth Advisors LLC increased its stake in Sanofi by 5,487.1% during the first quarter. Aaron Wealth Advisors LLC now owns 415,289 shares of the company’s stock worth $8,089,000 after purchasing an additional 407,856 shares during the period. 12.82% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

The Fly logo

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Want More Great Investing Ideas?

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.